Logotipo de Valence
populares
Iniciar sesión

Añadir a la lista de seguimiento

Aldeyra Therapeutics Inc.

NasdaqCM: ALDX · Precio en tiempo real · USD
1.56
+0.01 (0.65%)
Al cierre: Aug 19, 2026, 2:26 PM

Aldeyra Therapeutics Inc. (ALDX) Stock Price, Analysis & Data

0.65%
Precio de compra1.15
Capitalización de mercado92.9M
Ingresos (TTM)n/a
Beneficio neto (TTM)-23.05M
Beta1.20
EPS (TTM)-0.38
Ratio PER (TTM)n/a
Adelante PE-5.6
P/B (TTM)2.45
P/S (TTM)n/a
Earnings DateNov 4, 2026
Precio de venta2
Volumen535,322
Volumen medio (20D)1,355,235
Abierto1.59
Anterior Cerrar1.55
Rango del día1.54 - 1.60
Rango de 52 semanas1.07 - 6.17
analistaStrong Buy
Precio objetivo7 (348.72%)
Dividendosn/a
Fecha ex dividendon/a

Acerca de ALDX

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. T...

[Leer más]
Industria Biotechnology
Sector Healthcare
IPO Fecha May 2, 2014
Empleados 6
Bolsa de Valores NasdaqCM
Símbolo bursátil ALDX
Sitio web https://www.aldeyra.com
Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Aldeyra Therapeutics fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -33.85M, una disminución de -39.4%.

Estados financieros

Pronóstico del analista

Según las calificaciones de los analistas de 4, la calificación promedio de las acciones de ALDX es "Strong Buy". El pronóstico del precio de las acciones a 12 meses es 7, que es Potencial alcista de 348.72% del último precio.

Previsiones bursátiles

Sorpresa de resultados

Aldeyra Therapeutics ha publicado sus resultados trimestrales en Aug 6, 2026:
  • Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.
  • EPS de -0.09 falla las estimaciones por -0.01, con 43.75% Crecimiento interanual.

    • Próxima publicación de resultados

    Está previsto que Aldeyra Therapeutics Inc. publique sus resultados el Nov 4, 2026, durante el horario de mercado.
    Los analistas proyectan ingresos de ... Actualizar
    news image

    2 meses hace · Simply Wall St.

    CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock

    Investors who take an interest in Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) should definitely note that the CEO...

    news image

    2 meses hace · MarketBeat

    Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment

    Aldeyra Therapeutics (NASDAQ:ALDX) Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, follow...

    news image

    2 meses hace · Simply Wall St.

    3 Promising Penny Stocks With Market Caps Reaching $300M

    The market remained flat over the last week, but it is up 26% over the past year, with earnings forecast to grow by 17% annually. Investing in penny stocks—once a buzzword but now more of a niche—can ...

    news image

    3 meses hace · Simply Wall St.

    Upstart Holdings Leads These 3 Stocks Estimated To Be Trading Below Fair Value

    Over the last 7 days, the United States market has risen by 1.1%, and over the past 12 months, it is up by an impressive 27%, with earnings expected to grow by 17% per annum in the coming years. In th...

    news image

    3 meses hace · Simply Wall St.

    3 Stocks That May Be Undervalued According To Analysts In May 2026

    Over the last 7 days, the United States market has risen by 1.1%, contributing to a remarkable 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environm...

    Página 1 de 2